You are here: Industry Insights > Molnupiravir

News List

Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19 Drugs
December 27, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization...
FDA grants EUA for Merck-Ridgeback’s oral Covid-19 antiviral molnupiravir Pharmaceutical-Technology
December 27, 2021
The authorisation is based on positive results from the Phase III MOVe-OUT trial of molnupiravir in adult Covid-19 patients.
Merck, Ridgeback to supply 1.75 million molnupiravir courses to UK Pharmaceutical-Business-Review
December 24, 2021
Molnupiravir is an orally administered form of a potent ribonucleoside analogue that blocks the SARS-CoV-2 replication. It is planned to be sold under the trademark Lagevrio in the UK.
FDA Gives OK to Merck Antiviral At-Home COVID-19 Pill drugs
December 23, 2021
Many Americans now have two oral antiviral pills that can be taken at home to treat a fresh case of COVID-19.
FDA Gives OK to Merck's Antiviral At-Home COVID Pill drugs
December 23, 2021
Many Americans now have two oral antiviral pills that can be taken at home to treat a fresh case of COVID-19.
UK government to purchase additional 1.75 million courses of Molnupiravir expresspharma
December 23, 2021
With this additional procurement agreement, which follows a previously announced agreement for 480,000 courses of treatment...
Merck to Supply Up to 1 Million Courses of Molnupiravir, an Oral Antiviral Medicine for the Treatment of COVID-19, to Canadian Govt AmericanPharmaceuticalReview
December 07, 2021
Merck has entered into a Supply Agreement with the Government of Canada for up to 1 million patient courses of molnupiravir, its investigational oral antiviral medicine for the treatment of COVID-19. This investigational medicine is being developed by...
FDA Advisory Committee Votes for Oral Antiviral Molnupiravir to Treat COVID-19 in High Risk Adults AmericanPharmaceuticalReview
December 02, 2021
Merck and Ridgeback Biotherapeutics provided the following statement at the conclusion of the FDA Antimicrobial Drugs Advisory Committee (AMDAC) regarding the Emergency Use Authorization (EUA) application for molnupiravir (MK-4482, EIDD-2801)...
FDA Panel Mulls Merck's Molnupiravir COVID-19 Antiviral Pill Drugs
December 01, 2021
A U.S. Food and Drug Administration advisory panel is meeting Tuesday to weigh both the safety and power of Merck's new antiviral pill in preventing severe COVID-19.
Merck's COVID-19 Pill Appears Effective, but May Pose Pregnancy Risks: FDA Drugs
November 30, 2021
Merck's experimental COVID-19 antiviral pill appears effective, but may pose risks for pregnant women, including birth defects and toxicity to developing fetuses, according to the U.S. Food and Drug Administration.

Previous page 1 2 3 4 Next page